ACHN

Achillion Pharmaceuticals, Inc.

A biopharmaceutical company that develops small-molecule drugs to treat serious diseases, best known for its work on hepatitis C virus inhibitors and later on complement-system therapies for rare blood disorders. Founded in 1998 in New Haven, Connecticut, the company was acquired by Alexion Pharmaceuticals in 2019, and its name comes from the Greek word for "a thousand ships," a nod to the fleet that launched the Trojan War. Its most notable product candidate, danicopan, targets the complement pathway for paroxysmal nocturnal hemoglobinuria.

No 8-K or 6-K filings recorded.